RxDoctor Payments Data

Gnanambal Manivel, MD

Internal Medicine · Sarasota, FLNPI 1053799536

Payments from drug & device makers

$1,470in general payments, 2019–2025

Across 69 payments — averaging $21.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$267
  • Lilly USA, LLC$259
  • Pfizer$204
  • Philips North America LLC$159
  • Boehringer Ingelheim$115
  • AstraZeneca$104
  • plus $362 from 9 others

What the payments were for

  • Food & beverage$1,470100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,470 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$78,248
Medicare patients
136
Services billed
1,805

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$83,152
JardianceEmpagliflozin44$58,494
MounjaroTirzepatide34$46,427
EliquisApixaban28$37,184
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$34,077
TrulicityDulaglutide24$22,815
FarxigaDapagliflozin Propanediol21$18,770
Tresiba Flextouch U-100Insulin Degludec16$16,335
XareltoRivaroxaban18$15,240
Spiriva RespimatTiotropium Bromide13$10,632
Breo ElliptaFluticasone/Vilanterol11$9,131
Albuterol Sulfate HfaAlbuterol Sulfate97$3,627
Atorvastatin Calcium442$2,766
Levothyroxine Sodium196$2,116
Rosuvastatin Calcium150$2,060

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$85$83,15265 claims
Lilly USA, LLCMounjaro, Trulicity$259$69,24258 claims
Boehringer IngelheimJardiance, Spiriva Respimat$115$69,12657 claims
GSKTrelegy Ellipta, Breo Ellipta$267$43,20837 claims
PfizerEliquis$204$37,18428 claims
AstraZenecaFarxiga$104$18,77021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →